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Clinical Trials in Cancer Research
by Edmund A. Gehan*
Thisisareviewpaperwhichgivesadiscussionofvariousaspectsofclinicaltrialsincancerresearch. Since
theconductofthefirst randomized controlled clinical trialincancerpatients inthemid-1950's, substantial
progress has been made in the utilization ofthe clinical trial technique for the evaluation of therapeutic
efficiacy. The importantelements ofa protocol are given with some discussion ofitems to beconsidered in
desgning a protocol. The types ofclinical trial (phase I, II, III) are defined, and the placeofeach phaseof
study in the context of the search for new treatments is delineated.
Acomprehensivediscussion isgivenoftheelementsinthecomparativeclinicaltrial(phaseIII), including
objectives, considerations in planning (comparability oftreatment groups, stratification ofpatients, feasi-
bility andsizeofstudy, andprospective versusretrospectivestudies). Briefdescriptions aregivenofdesigns
forcomparativeclinicaltrialsandatrialinoatcell lungcarcinoma isdiscussed in somedetail. Finally, some
comments and references are given concerning the analysis of clinical trials.
Introduction
The randomized clinical trial was first used forthe
evaluationofcancertreatments inthe mid-1950's(1).
Inonly two decades, it has proven to be auseful way
ofevaluating the relative effectiveness oftreatments
and a substantial body of knowledge has been de-
veloped which provides objective data about cancer
treatments. The organization ofcomparative clinical
trials through the cooperative groups program spon-
sored by the National Cancer Institute in the U.S.
and clinical trials organized in other countries have
led to more uniform criteria for diagnosis, objective
definitions of response, protocols for the evaluation
of treatments, and statistical evaluation of results.
The design ofclinical cancer research studies rep-
resents a cooperative effort between clinicians and
statisticians in the design and analysis ofstudies and
between clinicians and patients in the conduct of
studies. The clinical trial is a device for obtaining
objective evaluations of the effectiveness of treat-
ments. All would agree that the treatment ofpatients
with cancer is not optimal and that better clinical
studies are needed to define better forms of treat-
ment.
In this paper, a description will be given of pro-
tocols in clinical studies, and the types of clinical
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trials being used in cancer research, with special
emphasis on the comparative clinical trial. For the
comparative clinical trial, discussion will be given to
objectives, considerations in planning, designs for
comparative studies, and analysis of clinical trials.
The overall objective will be to give an introduction
to the field with appropriate references to work that
has been accomplished.
Some recent articlesgiving adiscussion ofgeneral
issues relating to cancerclinical trials are Gehan and
Schneiderman (2), Livingston and Gehan (3), and
Peto et al. (4).
Protocols in Clinical Trials
Since any scientific clinical study requires a well-
developed experimental plan, all ctinical trials
should have aprotocol which outlinesthe design and
methodofconductoftheclinical trial. Aprotocolis a
written document which gives the purpose of the
clinical study including the rationale, the method of
administering the treatment(s), and details concern-
ing the plan of investigation. The usual elements
included in a protocol are (1) introduction and scien-
tific background for the study; (2) objectives of
study; (3) selection of patients; (4) design of study
(including schematic diagram) (5) treatment pro-
grams; (6) procedures in event of response, no re-
sponse, or toxicity; (7) required clinical and labora-
tory data; (8) criteria for evaluating the effect of
treatment; (9) statistical considerations; (10) in-
October 1979 31formed consent; (11) record forms; (12) references;
(13) study chairman or responsible investigator and
telephone number.
The first requirement of a good study is that it be
addressed to an important clinical question. If the
design, conduct, and analysis are perfectly carried
out but the question is trivial, then the study will be
trivial. The protocol should include a statement of
theobjectives ofthe clinical study which are specific
andwell-defined. These may bedivided into primary
and secondary objectives, and the design of the
study should ensure that at least all the primary
objectives are achieved. For example, in a study of
adult patients with acute leukemia, a clinical trial
might be designed to compare treatments for induc-
ing remissions, treatments for maintaining complete
remissions, and whether different types of im-
munotherapy treatment would be useful after a pa-
tient has been in remission for one year. Ifthe latter
were considered a primary objective, then sufficient
patients would have to be entered into study so that
the required numbers of patients were on each im-
munotherapy treatment among patients having re-
missions lasting at least one year. Since only 35-40%
ofpatients will achieve this status, it is evident that
rather large numbers of patients may have to be
enteredinto studytoachieve aprecisecomparisonof
the immunotherapy treatments. However, if com-
parison of the immunotherapy treatments was con-
sidered a secondary objective, sufficient patients
could be entered into study to achieve precise com-
parisons of remission induction and remission
maintenance treatments and simply analyze what-
ever numbers of patients receive the different im-
munotherapy treatments.
It is usually not a good idea to plan a study that
involves a large number of questions. Such studies
are more difficult for investigators to carry out, re-
quire more monitoring ofpatients and completion of
forms, aremoresubjecttochanges instudyplan, and
are often difficult to interpret clearly. It is usually
better to have a simple design of study which is
addressed toasmallnumberofimportantquestions.
The protocol should contain the preclinical and
clinical rationale fordoingthe study inthe contextof
areview ofpertinent recent data in the tumors to be
studied. The protocol should give the primary rea-
sons for undertaking the study and the scientific
basis for the choice of treatments.
The section on selection ofpatients should define
which patients are eligible for study and which will
be excluded. Ideally, the patients entering study
should be considered as a representative sample
from the population of possible patients who meet
the selection criteria. Pathological confirmation of
diagnosis is a requirement in nearly all studies and
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should be indicated in this section. Further details
that might be given are: tumor site(s) ortype(s) to be
studied; type (oramount) ofpriortherapypermitted;
age restrictions; requirements about renal and/or
liver function and bone marrow status; and require-
ments concerning the measurability of lesions.
Itisdesirabletokeep alogbookofallpatients seen
during the study period who have a confirmed diag-
nosis of the disease and are possible candidates for
study. The clinical investigator should record data
on characteristics related to prognosis, such as age
and stage ofdisease. If a patient is not entered into
study, a reason should be given. A log book permits
the clinical investigator to make statements about
the characteristics ofthe population ofpatients who
are candidates for study and the proportion of this
populationthathasbeenenteredintostudy. Changes
in the selection criteria might be made if too many
patients are being excluded.
The section on design of study should give a de-
tailed statementofthe courseofapatient'streatment
on the protocol. If the course is divided into parts,
such as induction, consolidation, and maintenance,
theprocedures tobefollowed ateach stage shouldbe
described clearly. It is helpful to include a schematic
diagram giving the general design of the study with
the treatments to be administered on specific days
following the start of study.
The section on treatment programs is that most
frequently referred to by physicians caring for pa-
tients and shouldgive precise statementsconcerning
the treatments to be administered. Treatment pro-
grams maybe defined in terms ofthe achievement of
agiven endpoint for the patient, for example a dose
ofdrug maybe givenaccordingto acertain route and
schedule until the white blood count performed at
stated intervals reaches a level of2000/mm3 or less.
The important point is to have a well defined treat-
mentprogramthatcanbefollowedbythephysician.
The section onproceduresineventofresponse, no
response, or toxicity should indicate what is to be
done to the patient in each circumstance. The gen-
eral steps should be indicated by the design of the
study, however the specifics in terms ofalternative
treatments, methods of handling toxicity, and re-
quirements for removal from study should be given
here.
The section on required clinical and laboratory
data gives the tests required for all patients prior to
entry into study and atdesignated time points during
the study. It is convenient if a table summarizing
these requirements is given in the protocol.
An important section of a protocol is that giving
the endpoints for evaluating the effectiveness of
treatment. In cancerclinical trials, typical endpoints
are response (complete remission, partial remission,
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vival time. In some types of cancer, for example,
advanced breast or lung cancer, the "no response"
category is sometimes subdivided into stable dis-
ease, mixed response, and disease progression. For
patients with advanced disease, achieving a state of
"stable disease" may occur more frequently with
one treatment than with another. For patients with
limited disease, such as certain patients with breast
cancer, treatment by surgery alone can remove all
evidence of disease. Endpoints for analysis in this
circumstance are "time to relapse" and "relapse."
Relapse may be defined as local recurrence of dis-
ease or occurrence of metastatic disease.
Thechoiceoftheprimary response variablehas an
importanteffectonthe numberofpatientsandlength
of study. If comparison is to be made between the
percentages ofpatients disease-free two years after
the startofthe study, thenthe studymustlast atleast
two years plus the length of time required to enter
sufficient patients into trial. Length of survival is
clearly an important endpoint; however, patients
sometimes die of causes not related to the disease
under study, may receive other treatments after re-
lapse onthe study, ormay have toolong anexpected
survival for a clinical trial of reasonable length. In
each clinical trial, various definitions of response
should be considered for their meaningfulness and
type of trial implied.
The section on statistical considerations should
summarize themajorobjectives tobe achieved inthe
study and give an estimate ofthe numberofpatients
required or of how the study will be analyzed se-
quentially as it proceeds. Some designs for clinical
trials comparing two or more treatments are the sim-
plerandomized design, the stratified randomized de-
sign, and the factorial design. The feasibility of the
study should also be considered in this section; if
estimates ofthe numberofpatients tobeentered into
study per month can be given based upon previous
data, the estimates should be given. An estimate
should be made ofthe total lengthoftimerequired to
accrue and follow sufficient patients to observe the
relevant endpoints and achieve major objectives.
Failure to give adequate consideration to the feasi-
bility ofstudy has resulted in the starting ofclinical
trials which had little or no hope ofbeing completed
with a definite statement about the effectiveness of
treatments.
In the United States, there is a requirement for
informed consent either from the patient or an indi-
vidual responsible forthe patient when the patient is
a child. As far as possible, the patient should be
informed ofthe design ofthe study and the rationale
for its conduct so that proper consent can be ob-
tained.
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Copies ofthe recordforms should eitherbe partof
the protocol or should be supplied in conjunction
withit. Therecordforms shouldcontainthe required
pre-treatment data and the data to be evaluated dur-
ing the course of study for each patient. Sufficient
information should be on the form so that an evalua-
tion can be made of whether or not the patient fol-
lowed the protocol properly and whether there was
sufficientobjectiveevidenceforresponse orrelapse.
It is usually helpful to have forms with boxes for the
recording of information that are self-coding, i.e.,
data can be entered directly into the computer by
keypunching from the forms or entry of data via a
computer terminal.
A protocol should be a self-contained document
and not have references to other protocols for items
such as definition ofresponse or method ofadminis-
tering treatment. When a protocol has been well
written, the final report ofthe study will be easierto
write.
Types of Clinical Trials
Figure 1 givesasequenceofclinicaltrialsforanew
agent. The diagram is given in terms of a chemo-
therapeutic agent, but similar steps are involved in
the development of new radiotherapy or surgery
treatments. New agents may reach the clinical trial
stage for various reasons: an indication ofeffective-
ness against cancer in animal systems (mice, rats,
dogs, and monkeys), as analogs ofagents that have
already proven effective, or as combinations of
single agents known to be of some effectiveness in
previous clinical studies.
Phase I Studies
The majorobjective ofthis trial isto determine the
maximum safely tolerated dosage regimen for a
given schedule of an agent in man. The regimen
should be one that can be used in looking for
therapeutic effects in later phases ofstudy. A major
aspect of the phase I trial is the elucidation of the
nature ofthe agent's side effects, both qualitatively
and quantitatively. The basic steps in the phase I
study are: selection ofa starting dose, selection ofa
methodfordoseescalation, and selectionofasample
ofpatients to receive the agent.
Studiesinanimal systemsprovideausefulguideto
the selection ofthe starting dosage in man. Freireich
et al. (5) have shown that the maximum tolerated
dose in man was comparable to that in five animal
species (mouse, rat, hamster, dog, and monkey)
when dosage was expressed per unit ofsurface area
in square meters. Hence, phase I studies in man
might be started at dosage levels of 1/3 or less ofthe
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(Phase I)
Purpose-
To determine a
dosage regimen
New m. that is not too
Agent toxic and can be
used in looking
for therapeutic
effect.
Preliminary trial
(Phase II)
Purpose-
To determine
whether a particular
dosage schedule
of an agent is
active enough to
warrant further
study.
Follow-up trial
Purpose-
To provide estimate
of effectiveness
of an agent
with specified
precision.
Comparative trial
(Phase III)
Purpose-
To decide whether
new therapy is
superior to standard
therapy.
effective in Phase I
trial.
high effectiveness in
Phase I or Phase II
trial.
Fig. 1. The sequence of clinical trials for a new agent.
average maximum tolerated dose per unit surface
areainthefiveanimal species oramoreconservative
procedure would be to use 1 the dosage in the most
sensitive animal species. These canonly be taken as
general guidelines, since as Freireich et al. (5) state:
"It is emphasized and should be clearly understood
that it isdangerous to attempt toextrapolate directly
from animal toxicity data to maximum tolerated
doses in man."
Selecting a method for escalating doses is not well
standardized. On assuming that no toxic side effects
have been observed at the starting dose level,
schemes suggested for increasing dosage may be
based upon a Fibonacci search technique (6) in
whichthedoseisraisedbydecreasingincrements, or
a simple percentage change in dose scheme based
upon toxicity observed. It is clearly desirable to
minimizethe numberofsteps required toreach some
evidence of biological effect, since neither useful
information nor benefit to the patient is obtained by
administering doses that are too low; on the other
hand, when some undesirable side effects have been
observed at a particular dosage, one must be ex-
tremely cautious in escalating dosage. As a general
guideline, it is advisable to have three patients on a
study ateachdoselevel andeach shouldbeobserved
until the period ofanticipated risk of acute side ef-
fects has passed.
The patient population chosen for a phase I study
can influence conclusions in a major manner, de-
pending upon the sensitivity of the patients to the
agent being studied. If only patients with very ad-
vanced disease are put on a phase I study, then the
dosage regimen recommended might be too low for
patients who were in an earlier stage of disease.
Every phase I study is at least in part a phase II
study. That is, there should be a definite searching
for evidence oftherapeutic response in the phase I
study.
Phase II Studies
The objective ofthe phase II trial is to determine
whetherthe particulardosage regimen chosen in the
phase I study is effective enough to warrant further
study. An agent would certainly be of interest if it
appeared substantially better than the existing best
treatment; alternatively, it could be of interest if it
had a lesser degree of activity but represented a
different type of agent or if the agent had lower
effectiveness but less toxicity.
Figure 1 indicates a category for a follow-up trial
which has the objective ofproviding an estimate of
effectiveness of the treatment regimen that has a
certain precision. An estimate of the approximate
effectiveness of an agent is desirable to have either
from the phase II or the follow-up trial prior to the
conduct of a phase III study.
A clinical trial is never a test of a drug or
radiotherapy or surgery. It is a test of a treatment
program when administered at a certain dosage, ac-
cordingtoacertain schedule, andin aparticulartype
ofpatient.
One of the following conclusions should be
reached at the end ofa phase II trial: (1) agent could
beeffective inX% ofpatients or more, or(2) agentis
unlikely to be effective in X% ofpatients or more. If
the objective can be stated in that manner, study of
only a relatively small number of patients might be
needed.
One approach to determining the minimum size of
sample forphase II studies has been given by Gehan
(7).Table 1 gives the numberofpatients necessaryto
have in a phase II trial to decide whether an agent is
worthy offurther study or is unlikely to be effective
inX% ofpatients ormore at given levels ofrejection
error. Rejection error p is the chance of failing to
send an agent on to further study, when it should
have been. Hence, ifone is interested in an agent of
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Therapeutic effectiveness, %
Rejection
error,f, % 5 10 15 20 25 30 35 40 45 50
5 59 29 19 14 11 9 7 6 6 5
10 45 22 15 11 9 7 6 5 4 4
20%o effectiveness and is willing to accept a 5% re-
jection error, a sample of 14 patients is needed. This
number has been derived by assuming that the true
effectiveness ofthe agent is 20%o and calculating that
the chance of 14consecutive failures is less than 5%.
Consequently, if all 14 patients fail to respond,
furtherstudy ofthe agentcould be stoppedbecause a
sequence of 14 failures would occur less than 5% of
the time if the true therapeutic effectiveness was
20%o.
The numbers in Table 1 should be taken as guide-
lines because several simplifying assumptions have
been made. First, response is assumed to be an all-
or-none phenomemon. Ifcomplete remission is the
endpoint, then nonresponse patients would be those
who showed no biological effect at all and also pa-
tients who showed some degree ofresponse thatwas
not sufficient to qualify for complete remission. Re-
sponse should be defined so that when one or more
such responses have been observed, it is meaningful
to study the agent further. Secondly, the numbers of
patients in the table assume that the chance of re-
sponse is the same for each patient. Based upon
previous studies, it is known that the chance of re-
sponse differs among individual patients according
to prognostic characteristics. Consequently, the
numbers inthe table are those assumingan "average
level" ofeffectiveness foreachpatient. Ifthere isnot
alarge amountofvariation around the average level,
the results in the table will be approximately correct
and not likely to lead to difficulties in particular
studies. Thirdly, nopriorinformationconcerningthe
agentis used inthe planningofthe study. Ifthe agent
has previously been included in a phase I study, it
may be desirable to combine the estimates ofeffec-
tiveness from the phase I and II studies, however no
allowance forthis is made inTable 1. Fourthly, ifthe
agent has already been studied in othertumortypes,
there is presumably some correlation between
chance ofresponse in various tumortypes; however
no allowance has been made for this.
The decision rule for a phase II study using the
number of patients in Table 1 is as follows: if all
patients inthe studydo notrespond, furtherstudy of
the agent is halted; ifone or more patients respond,
additional patients are added to study to determine
an approximate estimate of effectiveness. Agents
with effectiveness substantially lower than that of
interest have a substantial chance ofbeing passed to
further study. Forexample, ifone enters 14 patients
in search ofan agent of20% effectiveness (with 5%
rejectionerror), there is morethana51% chancethat
one or more responses will be observed even if the
agent has only 5% true therapeutic effectiveness.
The numbers ofpatients given in Table 1 represent
the minimum needed to reject an agent for further
study, given that no responses have been observed.
Passing an agent on for further study when the true
response rate is low might be acceptable when no
agent of any real effectiveness exists for the given
disease, but it may not be satisfactory for diseases
for which agents ofmoderate to high order ofeffec-
tiveness already exist.
There are alternative methods of specifying a
number of patients for phase II studies. A method
incorporatingdecision theory criteriahasbeengiven
by Sylvester and Staquet (8).
When adosage regimen has passed a phase II trial
or has been of moderate effectiveness in a phase I
trial, follow-up studies will be instituted to obtain a
more precise estimate of effectiveness. Gehan (7)
has given the number of additional patients to be
studied corresponding to number of responses ob-
served in the phase II study.
Some clinical investigators have suggested that
two dosage regimens or two types ofchemotherapy
should be randomized in a phase II trial. In essence,
the proposal is for the conduct of two .concurrent
phase II trials, since there is no objective of deter-
mining which ofthe two therapies is superior. Ran-
domizing patients between therapies provides some
control over the investigator's selection of patients
for study. If this is likely to be a problem and if
sufficient patients are available for conducting two
studies at the same time, then randomization of pa-
tients in phase II studies might be worthwhile.
Asallphase I studies have someelementsofphase
II, many phase II studies are concerned with phase I
problems. In studies of a single agent, cumulative
side effects may be observed in the phase II study
that were not observed in the phase I study, e.g.,
studies ofadriamycin and daunorubicin cardiac tox-
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(3)ofsomeoftheclinical aspectsofphase II studies.
The Comparative Clinical Trial
(Phase 111)
A comparative clinical trial is a planned experi-
ment in human patients involving two or more treat-
ments when the primary purpose is to determine the
relative effectiveness ofthe treatments. A phase III
trial might be begun when there is a preliminary
estimate ofeffectiveness ofanewtherapyfromprior
phase I orII studies. Acommoncircumstanceforthe
phase III trial is to compare aproposed new therapy
with the best standard treatment for the disease
being studied. A phase III trial should begin before
opinions have become fixed concerning the relative
value of the new treatment; this would make it dif-
ficultorimpossibletodoacontrolledtrial. However,
a phase III trial should not be undertaken when the
treatment programs are likely to be modified fre-
quently. In this circumstance, further patients
should be added to the phase II study.
These general considerations suggest that the
place for the phase III study-is when the proposed
new therapy has a potential for a small to moderate
sizedadvance ineffectiveness overthebeststandard
treatment. If there is no possibility of an advantage
for the proposed new therapy, then there is no real
rationale for a phase III study. If the new therapy
appears very significantly superior to the standard
therapy based on phase I or II studies, then it may
not be ethical to do a study in which patients would
be randomized between the new and standard treat-
ments.
Objectives
The type ofcomparative trial to undertake differs
according to the precise meaning of "determining
the relative effectiveness of the treatments." If the
primary aim is to select the better of the two treat-
ments for use in future patients and estimation of
effectiveness is secondary, then some type of se-
quential study should be conducted in which the
decision to continue study at any stage would be
determined by the results available at that stage. As
soon as itcould beconcluded that one treatmentwas
superior to the other, the study would be stopped,
eventhough atthat point it might be thatonly impre-
cise estimates ofthe effectiveness ofeach treatment
could be made. Alternatively, the objective mightbe
toselectthe bettertreatment and have anestimate of
theeffectoftreatmentwith someprecision. Withthis
combined objective ofselecting the bettertreatment
and estimating effectiveness, a sufficient number of
patients should be entered on each treatment so that
the effectiveness of each could be estimated with
some precision. Additional patients might then be
needed to satisfy the selection requirement.
As an example, a study by Freireich et al. (9)
involved a randomized, double-blind comparison of
6-MP versus placebo in the maintenance of remis-
sions in acute leukemia. The trial was a sequential
one in which patients were paired at each institution
according to complete or partial remission and pa-
tients were then randomized within pairs to 6-MP or
placebo. A preference was recorded for 6-MP or
placebo depending on the length of remission fol-
lowing each treatment, and there was a sequential
stopping rule which permitted the study to be
stopped after the accumulation of 18 pairs of pa-
tients. At that time, the median length of remission
for 6-MP was 27 weeks compared with 9 weeks for
placebo treatment. At the time the study was
stopped, it was clear that 6-MP was the superior
treatment, however only relatively imprecise esti-
mates of length of remission could be made based
upon 18patients. Yet, the estimatesofmedianlength
of remission were quoted by many clinical inves-
tigators without indication of the precision of the
estimates. This is anexample ofa study in which the
aim was to select the better treatment and estimate
effectiveness, however the sequential plan was de-
signed to permit only the selection of the better
treatment.
For each particular clinical trial, the primary ob-
jectives should beconsideredcarefully andthe study
design chosen to permit the achievement of major
objectives in a reasonable period of time.
Considerations in Planning
Factors to be considered in planning clinical trials
are: comparability of groups of patients, stratifica-
tions of patients, feasibility and size of study, and
prospective versus retrospective studies.
Comparability of Groups of Patients. Having
comparable groups ofpatients is asine qua non ofa
controlled clinical trial (10). A comparative clinical
trial should be so planned that the only explanation
ofadifferenceobservedbetweentreatmentgroupsis
aresult ofthe treatment and not differences in types
ofpatient oneach treatment. Thisrequires compara-
bility ofpatients when entered into study, duringthe
conduct of the study, and at the time of analysis
when the study is completed.
Randomization ofpatients is atechnique designed
to achieve comparability of patients between treat-
mentgroups attime ofentry into study. Randomiza-
tion assures that patients will be comparable on the
average with respect to factors influencing prog-
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dures adjusting for differences in prognosis can be
utilized so that appropriate tests of difference be-
tweentreatments can becarried out(11). Procedures
forrandomizing patients aredescribed by Gehan and
Schneiderman (2).
In a retrospective study, patients on a proposed
new therapy would be compared with patients
treated in the past, a historical control group. When
patient characteristics related to prognosis are
known, patients from the historical control series
can be compared with the current series of patients
using regression techniques to adjust for differences
in prognosis. Procedures for applying adjustment
techniques in clinical trials are described in Gehan
(12), and an application is made to studies ofbreast
cancer. Anassumption is needed inthis analysis that
the differences between treatment groups cannot be
explained by factors associated with chronological
time; hence, the use ofretrospective studies may be
expected to have more validity when the interval
between groups in chronological time is short.
To achieve comparability, it is also necessary to
manage patients on each treatment regimen in the
same way. Decisions concerning the removal ofpa-
tientsfrom studyorto stop treatmentbecause ofside
effects to the patient should be made utilizing the
same criteria. If some investigators have a prefer-
ence for one of the treatments so that patients are
maintainedonitlonger, orareclassifiedastoxiconly
when the toxicity is very severe, results could be
biased in the direction of the preferred treatment.
One solution is to do a double-blind study in which
neither the patient nor the physician is aware ofthe
treatment being administered. In cancer clinical
studies, double-blind studies tend notto be effective
in reducing bias because different types of treat-
mentsgenerallyleadtodifferenttypesoftoxicity and
the types of toxicity are known to the physicians.
Double-blind studies are most useful when the mea-
sure of response is subjective. The more objective
the criteria for toxicity and response, the less the
need for a double-blind study. In some circum-
stances, double-blind studies cannot be carried out,
such as studies of some surgical or radiotherapeutic
procedures.
Patients in each treatment group should be com-
parable with respect to the criteria applied in the
analysisofthe study. Hence, ifresponse isdefinedas
a 50%o reduction in the sum of the products of the
measured diameters of the tumors, then the same
criteria should be applied in both groups. In addition
to the investigator treating the patients, it is impor-
tant to have either a study chairman or reviewing
investigator evaluate the patient to assure the appli-
cation ofuniform criteria. Evaluation ofresponse of
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the patient can be made with the evaluator being
unaware ofwhich treatment the patient received. In
cooperative groups engaged in clinical trials, often
each patient is evaluated by a committee and objec-
tive criteria are utilized. This tends to diminish the
possibility of bias of a single investigator.
Stratification of Patients. Patients with any
given type ofcancer may differ in prognosis accord-
ing to such characteristics as age, stage of disease,
bone marrow status, and prior therapy. In adult
acute leukemia, for example, patients can be
categorized by age, infection status (yes orno), type
of leukemia, platelet count, and hemoglobin value.
Should important prognostic characteristics be
utilized to define stratifications of patients within
which patients would be expected to be comparable
in prognosis? In a randomized study, patients could
be randomized to the possible treatment groups
within each stratum. Alternatively, a randomized
clinical trial could be carried out by randomizing
patients to treatments without regard to strata. A
recent paper giving arguments for and against
stratification in clinical studies is that ofBrown (13).
Those arguing in favor of stratification state that
the treatment groups will be more comparable than
when prognostic factors are ignored; lack of com-
parability of groups can still be adjusted for in the
analysis; not stratifying patients leads to tests of
difference between treatment with less sensitivity
and power; and the balancing of patients on each
treatment within all subgroups makes it possible to
estimate and test for interaction effects. Peto et al.
(14) have argued that even when prognostic factors
are ignored in making treatment assignments, ran-
domization will tend to balance the treatment alloca-
tions within each stratification group. It can be
shown that when there areN patients in a given cell,
the amount of information achieved by complete
balance, thatisbyassigningexactlyone-halfoftheN
patients to each treatment, can be achieved on the
average by randomly assigningN + 1 patients to the
treatment armswithout regardtobalance. Secondly,
theyargue thathavingdifferent stratifications makes
the design and conduct of a clinical trial more com-
plex,possiblydiscouragingphysiciansfromentering
patients. Thirdly, it is pointed out that use of prog-
nostic factors for balancing treatment groups does
not eliminate the necessity for utilizing these vari-
ables in the statistical analysis. Hence, when multi-
ple strata are part of the design of the study, these
stratifications must be used in the analysis. Brown
(13)finds the arguments againstthe use ofprognostic
factors in randomization of treatment assignments
"logically valid but not persuasive." He argues that
one should not randomize without stratification, a
procedure that would perform well on the average,
37when one can achieve balance by stratification.
Though the loss of information per cell might be
small, a study with a large number of cells would
have alarge lossofpower. Assignment ofpatients to
stratais a simple procedure and notlikely todiscour-
age investigators from entering patients. Brown (13)
argues for stratification because of the increased
power and precision of the study.
Pocock and Simon(15) give methods forachieving
a balance ofpatients on each treatment with respect
toprognostic factors. Ifthe assignmentofpatients is
being made at multiple institutions, it is nearly al-
ways desirable to balance patients at each institu-
tion; failure to do this will result in some inves-
tigators criticizing the experimental plan because of
the divergences in number ofpatients on each treat-
ment.
Feasibility and Size ofStudy. Each clinical trial
should be considered for feasibility, number of pa-
tients required, and length of study. An important
consideration in planning a clinical trial is the num-
ber of patients per year that might be expected to
enter study. Having an estimate ofthis number and
knowing the approximate follow-up period for ob-
servation of an endpoint in the average patient will
make iteasiertodetermine the numberofpatients to
enterinto study. Clinical trials should notbe planned
to last for too long a period, since interest and moti-
vation of the clinical investigators tend to decrease
with time. Also, alternative treatments are likely to
be discovered and become candidates for compara-
tive studies.
The size of a comparative clinical trial is usually
determined by considering the clinical trial as a test
ofanull hypothesis versus an alternative. Sufficient
patients are entered into study to provide an ade-
quate test ofthat hypothesis in terms ofsignificance
level and power. Forexample, in aclinical trial ofA
versusB, thenullhypothesis mightbethatthere isno
real difference in the response rate to A or B, while
thealternative hypothesis might specify thatthere is
some real difference in response rates. The one-
sided alternative specifies the direction ofthe differ-
ence (response rate to A being higherthan that to B,
say), whereas a two-sided alternative specifies that
either A or B may have the higher response rate.
Tables2and3givethe numberofpatients required
in each of two treatment groups to test for given
differences in response rate at a certain significance
level and power of test. Table 2 gives the sizes of
study needed for the one-sided test, i.e., when the
clinical trial is designed to test whether a new treat-
ment is better than a standard. Table 3 gives the
numberofpatients required foratwo-sided test, that
iswhich ofthe two treatments is better. The clinical
investigator should specify the difference in re-
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sponse rates to be determined, an estimate of the
response rateforone ofthe twotreatments, the level
ofstatistical significance (a), the value ofthe desired
power(1 - f8), andwhetherthe testshould be one- or
two-sided. Thelevelofsignificanceaisthechanceof
false positive error, that is that the trial results in a
statement that there is a real difference between
treatments when infact there is none. The chance of
afalse negative erroris,f, thatis, the trial results in a
statement that there is no difference between treat-
mentswhen, infact, there is. The powerofthe testis
defined as (1 - f8).
As an example using Table 2, suppose that40Wo of
patients are expected to respond to standard treat-
ment, the clinical trial is to be conducted to deter-
mine whether aproposed new treatment results in a
response rate that is 20Wo higher and it is desired to
use a statistical significance level of5% and a power
oftest of80o. FromTable 2, the numberofpatients
needed in each group to meet these requirements is
76. If the desired power is 90% and the other re-
quirements are the same, then 105 patients are
needed in each group. The higherthe powerneeded,
the larger the number of patients. Also, the higher
thesignificance level(i.e., the smallertheprobability
that the observed difference is due to chance) used,
the larger the number of patients needed. For ex-
ample, if the clinical trial is supposed to be con-
ducted using a significance level of 1% and a power
of95%, 195 patients would be needed in each group.
If the set-up for the clinical study was the same,
except that it was desired to conduct a two-sided
test, then reference to Table 3 shows that 97 patients
would be needed in each treatment group (signifi-
cance level 5%, poweroftest80%). Clinical trialsfor
testing two-sided alternative hypotheses always re-
quire larger sample sizes than equivalent trials for
one-sided alternatives.
If the clinical trial were conducted strictly as a
hypothesis-testing procedure, then the given num-
bersofpatientswould be enteredintoeach treatment
group, response rates determined, and a statistical
test carried out to determine whether the difference
in outcomes was statistically significant at the 5%
level or not. Clinical trials are rarely, if ever, con-
ducted with this degree ofrigidity so that the sample
numbers of patients should be considered as guide-
lines in the planning stages ofthe study. Sometimes,
in fact, the procedure for determining sample size is
applied in reverse. For example, if 100 patients are
expected to enter study per yearin aone-sided com-
parisonofA versus B with aresponse rate of40%for
B, at about one year when 96 patients have been
entered, a 25% advantage in response rate for treat-
ment A could be detected (statistical significance
level 5%, power of test 80%). At about 1½2 years,
Environmental Health PerspectivesTable 2. Number of patients needed in an experimental and a control group for
a given probability of obtaining a significant result (one-sided test).
Smaller Number of patients at various
proportion larger minus smaller proportion of success (P2 - P1)a
of success
(P1) 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70
0.05 330 105 55 40 33 24 20 17 13 12 10 9 9 8
460 145 76 48 39 31 25 20 19 15 13 11 10 9
850 270 140 89 63 37 41 34 21 25 22 18 16 14
0.10 540 155 76 47 37 30 23 19 16 13 11 11 9 8
740 210 105 64 41 38 30 24 20 17 15 12 11 10
1370 390 195 120 81 60 46 41 35 28 24 20 17 16
0.15 710 200 94 56 43 32 26 22 17 15 11 10 9 8
990 270 130 77 52 43 34 26 23 19 16 12 11 10
1820 500 240 145 96 69 52 41 37 30 24 22 18 16
0.20 860 230 110 63 42 36 27 23 17 15 12 10 9 8
1190 320 150 88 58 46 36 29 23 18 16 12 11 10
2190 590 280 160 105 76 57 44 39 30 27 22 18 16
0.25 980 260 120 69 45 37 31 23 17 15 12 10 9
1360 360 165 96 63 46 38 30 23 18 16 12 11
2510 660 300 175 115 81 60 46 40 33 27 22 17
0.30 1080 280 130 73 47 37 31 23 17 15 11 10
1500 390 175 100 65 46 38 30 23 18 16 12
2760 720 330 185 120 85 61 47 39 32 24 20
0.35 1160 300 135 75 48 37 31 23 17 15 11 - -
1600 410 185 105 67 46 38 30 23 18 15
2960 750 340 190 125 85 61 46 39 30 24
0.40 1210 310 135 76 48 37 30 23 17 13 -
1670 420 190 105 67 46 38 30 23 17
3080 780 350 195 125 84 60 44 37 28 - -
0.45 1230 310 135 75 47 36 26 22 16 -
1710 430 190 105 65 44 36 26 20
3140 790 350 190 120 81 57 41 34 - -
0.50 1230 310 135 73 45 36 26 19
1710 420 185 100 63 41 35 24
3140 780 340 185 115 76 52 39
aModified fromCochranandCox. (36). Upperfigure: testofsignificance at0.05 fora, powerequals0.8for(1 -sf3); middlefigure: testof
significance at 0.05 for a, power equals 0.9 for (1 - f8); lower figure: test ofsignificance at 0.01 for a, power equals 0.95 for (1 - B).
after 152 patients had been entered, it would be pos- treatment is about 45%, the response rate for the
sible to detect a20Woadvantage fortreatment A over proposed new treatment is 50% and the research
B (statistical significance level 5%, power of test paperreporting the results ofthe study states "there
80o). At about 23/4 years when about 270 patients is no evidence in this study of a real difference in
have been entered, it would be possible to detect a response rates between A and B at the 5% level of
15% advantage fortreatment A with the same signifi- statistical significance." Reference to Table 3 in the
cance level and power requirements. The choice of rowfor smallerproportion ofsuccess equal 0.45 and
sample size and length ofstudy could be determined the column for larger minus smaller proportion of
by the clinical investigators to be consistent with the success equal 0.40 shows that 25 patients in each
response rate that might be expected for treatment group would have had reasonable power (80%) for
A. detecting a 40%o difference in response rates. The
Another way ofusing Tables 2 and 3 is to obtain a column for larger minus smaller proportion equal
rough estimate of the difference in response rates 0.45 shows that 24patients in eachgroup would have
that had a reasonable chance of being detected in a had a 90%o power for detecting a 45% difference in
given clinical study. For example, suppose aclinical response rates. Hence, a study with only 25 patients
trial has been conducted with 25 patients in each ineach groupmighthave missed a 10-25%advantage
treatment group, the response rate of the standard in response rates for treatment A. Rough interpola-
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39tion of the tables could be used when the actual continuing study at any stage based upon the
number ofpatients in the study does not correspond analysis ofresults atthat stage. The majorreason for
to numbers given in the table. conducting a sequential trial should be to enable the
George and Desu (16) give the number ofpatients clinical investigators to stop the study as soon as the
needed in clinical trials for comparing two survival observed difference is large enough to reject the
distributions when survival is assumed exponen- hypothesis that no real difference exists. Sequential
tially distributed. The numbers ofpatients specified plans forboth quantitative variables (such as degree
are the numbers offailures that must be observed in ofresponse) and qualitative variables (such as com-
each treatment group. Also, they give estimates of plete remission or not) are given. Sequential plans
the length of study required, assuming certain entry are "closed," meaning that there is a fixed upper
rates ofpatients per year. Table 2 or 3 could be used limit for the number of patients. This is especially
for this problem also assuming that the clinical in- desirable in clinical trials.
vestigators wish to determine whetherornot agiven Prospective versus Retrospective Studies. An
difference in proportion surviving a given period of important issue in planning a comparative trial is
time exists between .the two treatment groups. whethertwoormoretreatments should becompared
Armitage (17) gives some closed sequential plans in a prospective, concurrently controlled, ran-
for comparing treatment groups. These plans are domized study or whether the new treatment could
applicable when it is desired to have the option of be compared with a historical control group. There
Table 3. Number of patients needed in an experimental and a control group for
a given probability of obtaining a significant result (two-sided test).
Smaller Number of patients for various
proportion larger minus smaller proportion of success (P2 - Pl)a
of success
(PO 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70
0.05 420 130 69 44 36 31 23 20 17 14 13 11 10 8
570 175 93 59 42 37 31 24 21 18 16 13 12 11
960 300 155 100 72 54 42 38 33 27 24 20 18 16
0.10 680 195 96 59 41 35 29 23 19 17 13 12 11 8
910 260 130 79 54 40 36 29 24 20 17 16 13 11
1550 440 220 135 92 68 52 41 38 32 26 23 19 17
0.15 910 250 120 71 48 39 31 25 20 17 15 12 11 9
1220 330 160 95 64 46 40 31 26 22 18 16 13 11
2060 560 270 160 110 78 59 47 41 35 29 24 21 18
0.20 1090 290 135 80 53 42 33 26 22 18 16 12 11 9
1460 390 185 105 71 51 43 33 28 23 18 16 13 11
2470 660 310 180 120 86 64 50 44 36 27 24 21 17
0.25 1250 330 150 88 57 44 35 28 22 18 16 12 11
1680 440 200 115 77 56 45 36 29 23 18 16 12
2840 740 340 200 130 95 68 52 45 36 29 24 19
0.30 1380 360 160 93 60 44 36 29 22 18 15 12 -
1840 480 220 125 80 56 46 36 29 23 18 16
3120 810 370 210 135 95 69 53 45 36 29 23
0.35 1470 380 170 96 61 44 36 28 22 17 13
1970 500 225 130 82 57 46 36 28 22 17
3340 850 380 215 140 96 69 52 44 35 26
0.40 1530 390 175 97 61 44 35 26 20 17
2050 520 230 130 82 56 45 32 26 20
3480 880 390 220 140 95 68 50 41 32
0.45 1560 390 175 96 60 42 33 25 19 -
2100 520 230 130 80 54 43 32 24 -
3550 890 390 215 135 92 64 47 38 -
0.50 1560 390 170 93 57 40 31 23
2100 520 225 125 77 51 40 29
3550 880 380 210 130 86 59 45 - - -
aModified from Cochran and Cox (35).
Upperfigure: testofsignificance at0.05 fora, powerequals0.8for(1 -f); middlefigure: testofsignificance at0.05fora, powerequals
0.9 for (1 - /8); lower figure: test of significance at 0.01 for a, power equals 0.95 for (1 - 1).
Environmental Health Perspectives 40are vocal adherents of both viewpoints and the ar-
guments for and against such studies will be sum-
marized here. The inherent difficulty is that the
human patient is the experimental unit in a clinical
trial and the design of the study should take due
account of this in contrast with studies in ex-
perimental animals.
Byar et al. (18) state that "randomized clinical
trials remain the most reliable method forevaluating
the efficacy of therapy." The major advantages of
randomization are first that "bias is eliminated in
the assignment of treatments (which) means that
treatment comparisons will not be invalidated by
selection of a patient of a particular kind, whether
consciously or not, to receive a particular form of
treatment." Secondly, "randomization tends to bal-
ance treatment groups in covariates (prognostic
factors), whether or not these variables are known.
This balance means that the treatment groups being
compared will ineffecttend tobetrulycomparable."
Thirdly, "randomization guarantees the validity of
the tests ofsignificance that are used to compare the
treatments." With respect to ethical considerations,
Byar et al. (18) dismiss ethical objections to ran-
domizing patients because physicians may disagree
about what the best treatment for a patient is in
certain circumstances. A physician in a randomized
clinicaltrial has made anintellectually honest admis-
sionthat he does not know the best form oftherapy.
Chalmers and Shaw (19) argued that "random allo-
cation ofpatients in a scientific trial is more ethical
than the customary procedure, that of trying out a
new therapy in an unscientific manner by relying on
clinical impression and comparison with past ex-
perience." Byar et al. (18) do not make a suggestion
about ethical implications when during the conduct
of a study results are accumulating in favor of one
treatment. In this circumstance, a physician may
wish to not randomize his patients, ifone treatment
is substantially superior to another. Reference is
made to the suggestion of Shaw and Chalmers (20)
that this problem is minimized if the results of the
trial are not made known to participating physicians
until a decision has been reached by an advisory
committee responsible for stopping the trial.
Cogent arguments for conducting nonrandomized
clinical trials in some circumstances have beengiven
by Gehan and Freireich (21), Gehan (22), and the
limitations ofthe randomized clinical trial have been
discussed (23). Proponents of the nonrandomized
study have argued that all knowledge is dependent
onhistorical data so there is good reason to consider
use of historical control patients. Even proponents
ofrandomized controlled studies must accept some
historical data, in particular, their own; otherwise,
their completed studies would have no predictive
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value for the future. Nonrandomized studies de-
signed to achieve the same objectives as randomized
studies require substantially fewer patients. If an
investigator is studying A (new treatment) versus B
(standard treatment) in a nonrandomized study and
is willing to assume that sufficient data are available
so that the response rate to the standard treatment
can be taken as a fixed quantity, say P, then the
number of patients required to compare response
rates ofA versus B at a given significance level and
power of test is only one-fourth that for an inves-
tigator who randomizes patients equally to A and B
(21). Thus, if patients are entered consecutively on
treatment A over a given period oftime rather than
being randomized to A versus B in a study with the
same objectives, then either the nonrandomized
study will be completed more quickly or a test of
difference of response rates will be accomplished
that is more sensitive to smaller differences in re-
sponse rates.
The major difficulty in conducting the non-
randomized studyhas been pointedoutby Byaretal.
(18) when they state that "using a control group
chosen by any method other than randomization re-
quires the assumption either that the control and
treatment groups are identical in all important vari-
ables except the treatment under study or that one
can correct for all relevant differences. In the latter
case, one must assume that all factors affecting
prognosis are known." Regression models can be
used to determine factors related to prognosis in
clinical studies (11), and either logistic regression or
Cox's regression model (24) can be used to test for
treatment differences adjusting for differences be-
tween groups with respect to prognostic factors.
When the time interval between the historical con-
trol and the current study is short, the assumption
that other factors (such as change in diagnostic pro-
cedure, supportive therapy, investigators) are not
likelytoexplaintreatmentdifferences isreasonable.
Since a comparative trial is usually not started
unless there is preliminary evidence in phase I or II
studies suggesting that the new therapy is at least as
good or possibly better than the old, clinical inves-
tigators are usually concerned with one-sided statis-
tical tests, that is whether the new therapy is better
than the standard or not. Ifthis is so, then the ques-
tion should be raised whether it is ethical to enter
patientsonthestandard treatmentwhenthereislittle
or no chance that it could be better than a new
therapy.
Atkins (25) succinctly stated the ethical responsi-
bilityofthestatistician involvedinplanning aclinical
trial. Simply stated, it is ifthe statistician waswilling
tohave himselforamemberofhisfamily as apatient
in a randomized clinical trial, then it is ethical.
41Otherwise, it is not. Each clinical trial being planned
should be considered from this viewpoint before
starting; trials should not be begun unless one would
be willing to be a participant in the study in approp-
riate circumstances.
In nonrandomized studies, there is no ethical di-
lemma for the clinical investigators either in having
to decide whether to randomize patients or whether
to stop a study early when results are favoring the
new treatment. In the nonrandomized study, the
clinical investigator should always be administering
the treatment program that is considered most likely
to succeed for his patients, comparisons of results
being made with previous studies. Itwill be easier to
recruit patients for such studies, since all patients
presenting for the trial can be offered the proposed
new treatment, rather than only a random chance of
receiving it. During the conduct of the study, ac-
cumulating results on the new treatment, whether
favorable or unfavorable to the proposed new treat-
ment, cause no special difficulties. Iffavorable, the
trial is simply continued until precise estimates of
effectiveness are available for the new treatment. If
unfavorable, standard statistical procedures for
comparing a new versus a standard therapy can be
utilized for comparing treatments; the trial can be
stopped when the proposed new therapy has little
chance ofbeing superior to the standard treatment.
Those favoring randomized studies have argued
that such studies are inherently more convincing to
other clinical investigators. It is argued here that no
singleclinical study, whetherrandomizedornot, will
be completely convincing until results have been
confirmed either by the same or otherclinical inves-
tigators. Confirmation of results will be easier to
seek when some promising results have been ob-
tained on the proposed new therapy.
The main advantages for nonrandomized com-
parative studies are: there is no need forthe use ofa
relatively inactive orpoor standardtherapy as acon-
currentcontrol; studies ofa newtherapy in consecu-
tive patients with comparison to a historical control
group are accomplished with fewer patients and
more quickly; there is assurance for the patient and
physician that the patient is being offered the treat-
ment that the physician considers best; and the rea-
sonableness of this approach for tumor types with
low accrual rates. To validly compare results in a
nonrandomized study with patients from a historical
control group requires knowing the factors that in-
fluence prognosis and using regression methods to
adjust for possible differences in prognostic factors.
Finally, it mustbeassumedthatdifferences whichdo
exist between groups (such as chronological time,
institution, availability of supportive therapy, etc.)
are not sufficiently strongly related to prognosis to
explain the differences between treatments ob-
served.
Randomized studies may be preferred to the non-
randomizedwhen: theclinical trial isthefirstone in a
particular tumor type, so there is no basis forchoos-
ing a historical control group; there is a long time
interval, say, fiveyears ormore, betweenthecurrent
and past studies so that substantial differences re-
lated to chronological time may exist; or when only
small differences are expected between the new and
old treatments and a large number of patients are
available so that the ethical dilemmadoes not apply.
There is certainly a valid role forboth prospective
and retrospective comparisons in phase III studies.
Neither the prospective nor the retrospective tech-
nique is better in all circumstances. Conducting ob-
jective, scientific clinicaltrials inwhichobservations
are recorded which differ significantly from those
made in the past forms the basis for new knowledge
and therapeutic advances in the treatment ofcancer
patients.
In circumstances when no firm decision can be
reached regarding whether a study should be ran-
domized ornot, acompromise solution is sometimes
chosen in which patients are allocated to the pro-
posed new versus standard therapy on a2:1, a 3:1 or
some other basis. Sufficient patients should be
studied on the control group so that a meaningful
comparison can be made with previous results for
the control group to determine whether any real
changes have taken place. If there have been no
significant changes, then results for the control
group can be combined between the current and
previous studies for comparison with the proposed
newtherapy. Pocock (26) has discussed the issues in
combining randomized and historical control groups
in clinical studies.
Designs for Comparative Studies
The earliestcomparative clinical trials came about
by chance, and Bull (27) gives some examples. De-
signs for comparative clinical trials are generally
rather simple from the statistical viewpoint. The
complexity in clinical trials tends to arise from the
multiple observations made on each patient, the dif-
ficulties encountered in following the protocol in
some patients, and in deciding whether to terminate
a clinical study depending upon observed results.
Complex designs have not generally been utilized
because the delicate balancing features of such de-
signs are more likely to be upsetby missing observa-
tions or complications created in patient manage-
ment.
Environmental Health Perspectives 42Simple Randomized Design. The simplest situa-
tionisoneinwhichpatients are randomizedtotwoor
more treatments without any attempt to group pa-
tients by prognostic characteristics. As patients be-
come available for study, they are assigned to one of
the treatments by aformal random procedure. Non-
comparability between groups must be accounted
for in the analysis. This is the design ofchoice when
patient characteristics related to prognosis are not
known orwhen patients in only a single category are
being studied. Usually, the randomization is re-
stricted so that after a certain number of patients
have been entered, an equal number ofpatients have
been assigned to each treatment.
Stratified Random Design. If patients can be
grouped into prognostic categories or strata such
that differences in outcome may be expected among
strata, then stratifications may be defined and pa-
tients assigned to one ofthe treatments within each
stratumbyrandomallocation. The simplestsituation
is that in which the strata are pairs of patients and
each patient in a pair receives treatment A or B by a
random allocation (paired comparison design).
In this type ofdesign, too many stratifications of
patients should not be defined. For example, in a
study ofacute leukemia where age, infection status,
type of leukemia, platelet count, and hemoglobin
value have been identified as related to prognosis,
too many categories ofpatients would be defined if
each of these characteristics were used in defining
stratifications. In the limit, as the number ofstratifi-
cations grows large, there would only be one patient
in each stratum and the advantages of stratification
would be lost. As arule ofthumb, no more thaneight
stratification categories should be defined, and pref-
erablyfour, since differences among up tofourprog-
nosticcategories would accountformajor sources of
variation and sufficient patients are usually available
to have a substantial number ofpatients within each
stratum.
Theadvantages anddisadvantages ofstratification
have been discussed previously.
Cross-Over Designs. A cross-over design is a
combination of the simple randomized and paired
comparison design in which each patient is used as
his own control. A common way of utilizing this
design is to administer the sequence oftreatments A
followedby B to halfthe patients andthe sequence B
followed by A to the other half. A patient is assigned
to one ofthe two sequences by a random allocation,
each treatment being administered when the pa-
tient's disease is in a comparable state.
In cancer clinical trials, there are practical dif-
ficulties with the cross-over design, since some pa-
tients may not survive long enough to receive both
treatments; alternatively, the patient may have an
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excellent response to the first treatment so that a
long period of time would be required before the
second treatment could be given. Because ofthis, it
is nearly always true that sufficient patients will be
accumulated in the first phase of study to obtain a
sensitive comparison of A versus B in different
groups ofpatients before substantial numbers ofpa-
tients are available who have received both treat-
ments in the sequence. Of course, there is also the
possibilityofcarryovereffects inwhichthe response
tothefirsttreatment in the sequence is related to the
chance ofresponse in the second phase. Cross-over
designs of A versus B in the same patient in cancer
clinical studies have been used to confirm the results
ofcomparing A to B in different patients. In studies
ofacute leukemia by Frei et al. (28) and Freireich et
al. (9), comparisons of treatment effectiveness
within patients confirmed the results ofcomparisons
between groups of patients.
Factorial Designs. A common situation in clini-
cal studiesoccurs when anumberoffactors are to be
studiedfortheirrelationshiptoresponse. Inthe2 x 2
factorial design, for example, two treatments (or
factors) each administered at two levels, say high
andlowdosage, maybe studiedfortheirrelationship
to response. The treatment-dosage combinations
definefourtreatmentcombinations towhichpatients
would be randomized. Such trials can be used for
testing possible interaction effects, that is whether
the difference in effectiveness between treatments
was maintained at both levels of dosage. Similarly,
differences between high and low dosage could be
examined for each treatment.
An example is given of a factorial design in the
next section.
Example of Clinical Trial
It is useful to discuss the planning of an actual
clinical study to be aware of issues that should be
considered in the planning of studies. This example
relates to a proposed clinical trial by Dicke et al.
(personalcommunication), though this study has not
yetbegun. The example is concerned with astudy of
patients with oat cell lung carcinoma; factors to be
studied are: protected environment status (PE) (yes
or no), marrow transplant (MT) (yes or no), and
chemotherapy treatment (two types). Based upon
the accrual of patients in previous studies, it was
estimated that 60 patients per year would be eligible
for study; however approximately one-third of the
patients would not be eligible for marrow transplant
because ofinvolvement ofthe bone marrow or clini-
calcondition. Themajorendpointsfortheevaluation
ofpatients were to be complete remission rate and
survival time after the start of study.
43Table 4. Design of study of oat cell lung carcinoma.a
Protected environment (PE)
No Yes
Marrow No 30 30 60
transplant
(MT) Yes 30 30 60
60 60 120
aStratifications of patients: limited or extensive disease am-
bulatory or nonambulatory; treatment groups and number of pa-
tients entered in 3 years: All patients receive chemotherapy.
Based upon previous studies ofchemotherapy in
oat cell lung carcinoma at M.D. Anderson Hospital,
acomplete remission rate of45% had been observed
with 50o of the patients surviving one year. It was
expected that patients in a protected environment
and receiving a marrow transplant with the same
type of chemotherapy might be expected to have a
superior complete remission rate and percentage of
patients surviving one year. Because ofvarious fac-
tors including expected period of support for the
study, it was desirable to have some results within
three years afterthe start ofthe study. Inthis period
oftime, it was expected that 180 patients would be
availableforstudy, 120ofwhomwouldbeeligiblefor
the marrow transplant program. Patients with oat
cell carcinoma can be stratified according to limited
versus extensive disease and ambulatory status or
non-ambulatory status.
A proposed factorial design for this study is given
in Table 4 with the expected numbers ofpatients on
each treatment combination over the three year
period. Because of the limited number of patients
available and the number oftreatment combinations
to be studied, it was decided that all patients would
receive the same chemotherapy program. The ob-
jective ofthe study was to determine whether any of
the treatment combinations yielded a significant im-
provement over the 45% complete remission rate
and/or 50%o of patients surviving one year.
For the purpose of planning the study, it was as-
sumed thattheeffectofthe marrowtransplantwould
be similar in patients in or out ofthe protected envi-
ronment so that a total of 60 patients receiving a
marrow transplant over the three year period could
becompared with60patients notreceivingamarrow
transplant. The same type ofassumption was needed
for protected environment patients so that it was
reasonable to compare the 60 patients treated in the
environment with 60 patients treated outside the en-
vironment.
Table 5 gives the statistical considerations for the
study. The simplifying assumption was made in de-
termining these figures that results could be com-
bined from the four stratifications of patients to
achieve an overall complete response rate and per-
centage ofpatients surviving a given period oftime.
It was anticipated that the percentage of patients in
the four stratification categories would be similar to
that in previous studies.
In Table 5, the first comparison is between the
total of 180 patients with oat cell carcinoma in the
three year period compared with the baseline fig-
ures. In making comparisons with previous results,
patients not eligible for the marrow transplant must
be included. Since it might be expected that patients
not eligible for a marrow transplant would be less
favorable than other patients, comparing results in
only the 120 patients eligible for marrow transplant
withprevious results could be subjectto severe criti-
cism. It could rightly be stated that a more favorable
group received the PE and MT and hence, overall
comparisons were not meaningful. Comparing re-
sults with the 180 patients with baseline data shows
that the power would be 80% for detecting an 8%
improvement in either CR rate or percentage sur-
vivingone year(statistical significance level 5%) and
a 90%o power for detecting a 15% improvement.
Table 5. Oat cell lung carcinoma: statistical considerations for study.a
Total Difference to Significance
Comparisons (one-sided) patients be detected, % level (a), % Power (I - /3), %
180 patients vs. baseline 180 8 5 80
15 5 90
PE vs. No PE or 1 120 22 5 80
MTvs. No MT 28 5 90
PE-MT vs. PE-No MT or 1 60 35 5 80
other subgroups j 40 5 90
aEndpoints: complete remission rate, survival; baseline data: 45% CR rate; 50%o survive I year.
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MT would be made based upon 60 patients in each
group or a total of 120 patients. This number of
patients would be sufficient to detect whether a PE
or the MT resulted in a 22% improvement in prog-
nosis compared with the absence of either of these
factors (statistical significance level 5%, power of
test 80O).
With the proposed design, there would be 30 pa-
tients within each subgroup, i.e., receiving both PE
and MT, etc. Comparisons of results among sub-
groups of patients would give an indication of
whether or not there were interaction effects. Com-
parisons between any two subgroups of 30 patients
would give an 80%o chance of detecting a 35% ad-
vantage in prognosis in one group and a90% chance
ofdetecting a40%o difference (statistical significance
level 5%). Though the design ofthe study is not very
sensitivetodifferences among subgroups, itmightbe
sufficient todetermine whetherthe directions ofMT
and PE effects were different depending upon the
presence or absence of the other factor.
Though this study has not yet been conducted,
discussion of the various factors involved should
give an appreciation ofthe issues to be considered in
the planning of an actual clinical trial.
Analysis of Clinical Trials
In the analysis of any comparative clinical trial,
therearetwoaspects: estimationoftreatmenteffects
and toxicity, and a test of whether or not there is a
real difference between treatments with respect to
the major endpoints being studied. The relative em-
phasis on estimation or testing depends upon the
objectives of the trial.
In any moderately large clinical trial, some pa-
tientswillbeenteredinto studywhowere noteligible
and other patients will not follow the treatment pro-
gram outlined in the protocol for some reason. As a
preliminary step in the analysis, patients should be
put in appropriate categories depending upon their
status. Some patients may be excluded from all re-
sults, while others might be included in some calcu-
lations. Itis recommended that patients firstbe clas-
sified according to whether or not they were eligible
for study according to the selection criteria and pa-
tientsthatarenoteligible shouldbeexcludedfromall
analyses.
If the analysis being performed is an interim
analysis during the conduct ofthe study, the eligible
patientscanbeclassified into thosewho aretooearly
to evaluate and those who have been evaluated for
response and toxicity. Patients who are too early to
evaluate must be excluded from all analyses. Pa-
tients who have been evaluated may be classified as:
evaluable, partially evaluable, or not evaluable. Pa-
tients are generally put in the not evaluable category
because of a major protocol violation (e.g., treat-
ment not given, treatment program deviated from in
amajorway, etc.), inadequate dataorotherreasons.
Patients may be classified as partially evaluable be-
cause of early death, lost to follow-up shortly after
the study was started, refused further treatment,
inadequate trialduetotoxicity, orotherreasons. Itis
recommended here that patients be identified who
have problems associated with their treatment so
that analyses can be performed including or exclud-
ing patients in certain categories. At our institution,
analyses are generally performed first on those pa-
tients who are fully or partially evaluable, that is
excluding patients that are not evaluable, not eligi-
ble, ortooearly to evaluate. In comparative studies,
differences inresponse rate betweentreatments may
depend upon the categories of patients excluded
from the analysis. A recommended procedure is to
calculate the differences in endpoints between
treatments in more than one way. If all ways of
comparing treatments lead to the same conclusion,
then there can be reasonable confidence that the
conclusion iscorrect. Ifthere is adifferencebetween
treatments that is statistically significant using one
denominator (say all evaluable patients) but is not
statistically significant for anotherdenominator (say
all eligible patients), then the conclusion regarding
the study depends upon the patients that were par-
tially or not evaluable. In such a circumstance, the
study shouldbe recordedas inconclusiveandfurther
patients entered until a conclusive statement can be
made. Peto et al. (14) argue that "rigorous entry
criteria are not necessary for a randomized trial, but
rigorous follow-up is. Even patients who do not get
thepropertreatmentmustnotbewithdrawnfromthe
analysis." While this may be an appropriate proce-
dure for determining whether it is better to be ran-
domized to onetreatment oranother, anobjective of
a clinical study is to estimate the effectiveness of a
given treatment. By including patients who may not
have received the treatment at all orwho received it
inamarkedlydifferent mannerfromthat specifiedin
theprotocol, one is likely to obtain abiased estimate
ofthe effectiveness of a given treatment. Including
allpatients randomized is abettergeneral procedure
than only considering "evaluable patients," how-
everthe recommendation here is to calculate differ-
ences in endpoints in multiple ways.
In all comparative trials, it is important to check
that patients entered on each treatment are compar-
able with respect to factors that might influence
prognosis. This is important both for randomized
and nonrandomized studies, and an analysis should
October 1979 45becarried outby use ofadjustment procedures, usu-
ally regression procedures, when patients are not
comparable with respect to important characteris-
tics. The use of regression procedures to adjust for
prognostic characteristics is described for cancer
clinical trials in Gehan (12).
In estimating treatment effects, the most mean-
ingful statistics for the physicians are the percen-
tages ofpatients having objective responses to each
treatment, disease-free survival curves, survival
curves, and other appropriate measures ofendpoint
in clinical studies. An estimate of variability of ap-
propriate statistics should begiven, such as standard
errorofthe percentage responding or standard error
ofthe proportion disease-free at two years. Report-
ing average values plus or minus two standard error
limits give approximate 95% confidence limits for a
true value and some measure of how precisely ef-
fects have been estimated. Peto et al. (4) give proce-
dures for estimating survival curves and tests for
differences between them. Gehan (29) has also re-
viewed statistical methodology appropriate for sur-
vival studies.
Inthefrequentist methodoftestingfordifferences
between treatment groups, a hypothesis is set up
which indicates no real difference in the effective-
ness oftwo treatments (null hypothesis) and the as-
sumptionis madethatthenull hypothesisistrue. The
significance level is the probability of obtaining a
sample difference as great or greater than that ob-
served, assuming that the null hypothesis was really
true. When the probability is low, say under 0.05,
most clinical investigators would be willing to reject
the hypothesis ofno real difference and declare that
some real difference exists in the measure of re-
sponse. Unfortunately, some clinical investigators
adhere too closely to 0.05 as the statistical signifi-
cance level. If the observed difference has a
statistical significance of 0.08, it is declared "not
significant" whereas if!it is 0.04, it is declared as
"statistically significant." Since the difference in
observed evidence against the null hypothesis be-
tween a significance level of 0.08 and 0.04 must be
small, itisbettertointerpret significance levels, orP
values, as a measure ofthe strength ofthe evidence
against the null hypothesis.
An overemphasis on significance level should be
avoided. Zelen, in an article by Cutler et al. (30),
pointedoutthat"thenumberofscientificpapersthat
use statistical methods for window dressing is in-
creasing. It appears that the P value next to a con-
tingency table is beginning to mean whatthe 'Seal of
Good Housekeeping' means to the housewife."
With the advent of the use of the computer for
analyzing clinical studies, it has become possible to
not only compare overall differences between treat-
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ments, but also to consider differences between
treatments within many subgroups of patients.
Often, it will be desirable to compare treatments
within age groups or patients grouped by stage of
disease, but there is a danger, as pointed out by
Tukey (31), that multiple tests of difference will be
carried out between groups, reporting only those
statistically significant at the .05 level. Tukey points
out that some adjustment should be made for the
number of classes of patients, k, that would have
been looked at seriously if the results for them had
seemed favorable'. It does not suffice fork to be only
as large as the number ofclasses actually looked at;
what is needed is the larger number ofclasses, each
ofwhich would have been looked at seriously ifthe
resultsforthemhad turned outfavorably. As arough
rule ofthumb, Tukey suggests working with a statis-
tical significance level of0.05/k when multiple tests
have been carried out.
Most clinicians understand the statement "Statis-
tical significance is not necessarily equivalent to
biological importance." The corollary of this state-
mentwhich is quoted less often is: "Not statistically
significant does not necessarily mean not biologi-
cally important." In randomized clinical trials in-
volving a small number of patients in each group,
there may be substantial differences between treat-
ment groups that are "not statistically significant."
Suppose, for example, that a randomized clinical
trialhas beenconductedwith25 patientsrandomized
to each of two groups. Suppose further that 11 pa-
tients or44% responded in one groupcompared with
5 patients or 20o in the other group. These results
lead to a chi-square value of 2.30 and a statistical
significance level between 0.05 and 0.10. Results of
this trial could be reported as "not statistically sig-
nificant," while there was a 24% difference in re-
sponse ratebetweenthetwo treatments. Toproperly
interpret the results of such a trial, the power ofthe
clinical trial fordetecting differences between treat-
ments shouldbegiven. Inthis particulartrial, having
25 patients in eachgroup would have given a reason-
able chanceofdetecting40%differences in response
rates between treatments (statistical significance
level 5%, poweroftest 80%). Freiman et al. (32) did
a survey of 71 negative randomized clinical trials.
Though the conclusion was negative concerning
treatment differences, the authors pointed out that
the power of the tests for detecting differences be-
tween treatments was very low. In 68% of the 71
trials, the confidence limitforthe difference in survi-
valincluded a50%o reduction in mortality and in 85%
ofthe trials, a 25% reduction in mortality was in the
95% confidence interval. Hence, this suggests that
many "not statistically significant" clinical trials are
being reported in the medical literature that may be
Environmental Health Perspectivesofmedical importance, but the sample size was not
sufficient to determine the degree of importance.
There are many statistical techniques for the
analysis and interpretation of clinical trials data. A
description of many appropriate procedures can be
found in the excellent textbook ofstatstical methods
of Snedecor and Cochran (33); statistical methods
especially useful in clinical trials have been given by
Armitage (34), Burdette and Gehan(35), andarecent
joint paper by Peto et al. (4).
Summary
This is a review paper which gives a discussion of
various aspects ofclinical trials in cancer research.
Since the conduct ofthe first randonized controlled
clinical trial in cancer patients in the mid-1950's,
substantial progress has been made in the utilization
of the clinical trial technique for the evaluation of
therapeutic efficacy. The important elements of a
protocol are given with some discussion ofitems to
be considered in designing a protocol. The types of
clinical trial (phase I, II, III) are defined, and the
place of each phase of study in the context of the
search for new treatments is delineated.
A comprehensive discussion is given of the ele-
ments in the comparative clinical trial (phase III)
including: objectives, considerations in planning
(comparability oftreatment groups, stratification of
patients, feasibility and size of study, and prospec-
tive versus retrospective studies). Briefdescriptions
are given of designs for comparative clinical trials
and a trial in oat cell lung carcinoma is discussed in
somedetail. Finally, some comments and references
are given concerning the analysis of clinical trials.
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